Catalyst Pharmaceuticals Inc (CPRX)

$12.18

-0.53

(-4.17%)▲

Market is closed - opens 7 PM, 21 Sep 2023

Insights on Catalyst Pharmaceuticals Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 85.36M → 99.58M (in $), with an average increase of 14.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 29.56M → 37.76M (in $), with an average increase of 21.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 91.9% return, outperforming this stock by 89.9%

Performance

  • $12.18
    $12.71
    $12.18
    downward going graph

    0.0%

    Downside

    Day's Volatility :4.17%

    Upside

    4.17%

    downward going graph
  • $11.09
    $22.11
    $12.18
    downward going graph

    8.95%

    Downside

    52 Weeks Volatility :49.84%

    Upside

    44.91%

    downward going graph

Returns

PeriodCatalyst Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-8.08%
0.0%
0.0%
6 Months
-26.32%
3.0%
-0.5%
1 Year
2.01%
7.2%
0.4%
3 Years
295.95%
27.5%
19.1%

Highlights

Market Capitalization
1.3B
Book Value
$3.52
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
0.99
PE Ratio
12.75
PEG Ratio
0.0
Wall Street Target Price
23.1
Profit Margin
38.14%
Operating Margin TTM
45.62%
Return On Assets TTM
24.29%
Return On Equity TTM
37.49%
Revenue TTM
302.9M
Revenue Per Share TTM
2.89
Quarterly Revenue Growth YOY
87.5%
Gross Profit TTM
160.0M
EBITDA
154.5M
Diluted Eps TTM
0.99
Quarterly Earnings Growth YOY
0.65
EPS Estimate Current Year
1.89
EPS Estimate Next Year
2.19
EPS Estimate Current Quarter
0.42
EPS Estimate Next Quarter
0.45

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Catalyst Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 89.66%

Current $12.18
Target $23.10

Technicals Summary

Sell

Neutral

Buy

Catalyst Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
-16.58%
-26.32%
2.01%
295.95%
303.49%
Moderna, Inc.
Moderna, Inc.
-3.91%
-29.82%
-15.12%
54.11%
473.87%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.9%
10.13%
22.22%
50.58%
114.4%
Novo Nordisk A/s
Novo Nordisk A/s
2.45%
29.29%
91.93%
176.03%
299.56%
Seagen, Inc.
Seagen, Inc.
7.77%
4.2%
47.16%
16.48%
167.89%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.14%
18.37%
27.77%
35.7%
98.94%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
12.75
12.75
0.0
1.89
0.37
0.24
0.0
3.52
Moderna, Inc.
Moderna, Inc.
35.66
35.66
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.39
22.39
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.6
43.6
2.03
3.3
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.47
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.75
27.75
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
Buy
$1.3B
303.49%
12.75
38.14%
Moderna, Inc.
Moderna, Inc.
Buy
$39.6B
473.87%
35.66
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.8B
114.4%
22.39
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$834.9B
299.56%
43.6
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$38.9B
167.89%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$92.5B
98.94%
27.75
35.4%

Institutional Holdings

  • BlackRock Inc

    14.87%

  • State Street Corporation

    8.87%

  • Deerfield Management Co

    7.69%

  • Vanguard Group Inc

    6.45%

  • Dimensional Fund Advisors, Inc.

    2.32%

  • Geode Capital Management, LLC

    1.81%

Company Information

catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso

Organization
Catalyst Pharmaceuticals Inc
Employees
82
CEO
Mr. Patrick J. McEnany
Industry
Health Technology

Discover More

FAQs